Elsevier Evidence-based Medicine Center Selects Doctor Evidence for Digital Clinical Evidence Platform

Doctor Evidence to provide a comprehensive clinical evidence platform to support Elsevier Clinical Solutions' global clinical product suite

Philadelphia, PA, July 23, 2014

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that Elsevier Clinical Solutions' Evidence-based Medicine Center (EBM Center) has reached an agreement with Doctor Evidence LLC (DRE) to provide the platform engine supporting the Clinical Solutions' suite of evidence-based clinical solutions.

"Doctor Evidence is tremendously excited to be working with the Elsevier EBM Center in providing physicians and patients with truly evidence-based clinical data," said Robert Battista, CEO and Co-Founder of Doctor Evidence. "Consistent with our company values, the most gratifying partnerships are the ones that have the potential to directly impact patients and improve their outcomes and well-being through the use of evidence. This engagement with the Elsevier EBM Center is one of those partnerships."

DRE will configure databases with high quality data from the medical literature pertinent to key clinical topics for the EBM Center, assuring that all the information is reliably and easily managed through a robust technology platform that is compliant with the standards set forth by the world's leading authorities on evidence-based medicine. DRE's Digital Outcome Conversion (DOC™) suite of products will provide the evidence foundation supporting Elsevier solutions such as ClinicalKey, InOrder by Elsevier, and other point-of-care decision support resources.

"Our suite of clinical solutions addresses some of the biggest challenges in healthcare by making clinical evidence available to professionals and patients at the right time and in the right setting," said David Goldmann, MD, Vice President and Chief Medical Quality Assurance Officer at Elsevier Clinical Solutions. Goldmann heads up the EBM Center.

"The EBM Center is charged with ensuring that Elsevier's clinical content is as high-quality and evidence-based as it can be. Among the many companies claiming to be able to meet our needs for extracting and synthesizing clinical data to support our activities, Doctor Evidence stands alone with its combination of people, process and technology," Goldmann said. "Doctor Evidence's platform will allow our team of methodologists and subject matter experts to conduct powerful analyses and to continually update the body of evidence supporting our clinical products."

---

About Doctor Evidence, LLCDoctor Evidence is a specialty software platform and services company aimed to assist stakeholders across the healthcare ecosystem to make and inform clinical decisions with the most relevant medical evidence. The Doctor Evidence methodology uses a Digital Outcome Conversion (DOC™) approach of taking data from static sources and to transform it into reusable, dynamic databases. The Doctor Evidence software platform empowers both public and private sector clients via programs like its GROWTH Collaborative.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Christopher Capot
Director, Corporate Relations
Elsevier
+1 212 633 3164
c.capot@elsevier.com